For laboratory and research use only. Not for human consumption.
Skin & Hair

Melanotan I

Also known as: Afamelanotide, Scenesse, MT-1, CUV1647

FDA Approved
Share:
Last reviewed

Key Facts: Melanotan I

Category
Skin & Hair
FDA Status
FDA Approved
Clinical Status
FDA Approved (2019) as the Scenesse implant for Erythropoietic Protoporphyria only. Injectable 'Melanotan I' research products are not FDA approved. The label calls for a full-body skin exam twice a year because it darkens existing moles.
Banned in Sport (WADA)
Not on the WADA Prohibited List (2026); as afamelanotide it is an approved drug, so the S0 catch-all does not apply.
Administration
Subcutaneous implant (not injection)
Typical Dose
500-1000 mcg daily (loading), then 500-1000 mcg 1-2x weekly (maintenance)
Frequency
Daily during loading (1-2 weeks), then 1-2x weekly maintenance
Duration
Long-term / as needed before sun season
Also Known As
Afamelanotide, Scenesse, MT-1, CUV1647

How does Melanotan I work?

Afamelanotide binds and activates the melanocortin-1 receptor (MC1R) on pigment-producing melanocytes, driving production of eumelanin, the dark, photoprotective form of melanin. Two amino acid swaps from natural alpha-MSH - norleucine at position 4 and D-phenylalanine at position 7 - make it bind MC1R more tightly and resist breakdown, so it lasts far longer and acts more potently than the native hormone. The extra eumelanin absorbs and scatters light and also brings antioxidant and DNA-repair-supporting effects, which is why it raises the light dose EPP patients can tolerate before pain hits. Unlike Melanotan II, it is selective enough toward MC1R that it is not primarily a sexual-function or appetite agent.

What does the research show?

This is one of the few peptides on this list with gold-standard human evidence. The pivotal data came from two multicenter, randomized, double-blind, placebo-controlled trials published in the New England Journal of Medicine in 2015 (Langendonk et al., 373(1):48-59), enrolling 168 EPP patients across the EU (74) and US (94) who received the 16 mg implant or placebo every 60 days. Afamelanotide significantly increased pain-free time in sunlight (median 69.4 vs 40.8 hours in the US trial; 6.0 vs 0.8 hours in the EU trial, where phototoxic reactions also dropped from 146 to 77), and improved disease-specific quality of life, with mostly mild adverse events. Long-term observational follow-up of EPP patients has supported continued benefit and an acceptable safety profile. Clinuvel is also running a phase 3 vitiligo trial (CUV105), with topline results guided for December 2026. The big caveats: this approval is narrowly for EPP, not for cosmetic tanning, and the unregulated injectable 'Melanotan' products people buy online are not the same controlled, clinician-administered implant and carry real risks. Bottom line: a genuinely proven, approved drug for a rare condition, frequently misused outside that lane.

Trial Progress:FDA Approved
Pre
I
II
III
IV
FDA

What doses have been studied?

FDA Approved·Human clinical trials completed, FDA approved

Typical Dosingⓘ

Community experience

Common Dose

500-1000 mcg daily (loading), then 500-1000 mcg 1-2x weekly (maintenance)

Range

250-1000 mcg per administration

Frequency

Daily during loading (1-2 weeks), then 1-2x weekly maintenance

Administered as MT-II is, with greater receptor selectivity and fewer reported sexual adverse effects. Reported onset of pigmentation is slower than with MT-II. The approved version, Scenesse, is an implant for EPP patients only.

Research Dosingⓘ

Scientific studies

FDA-approved dosing for EPP

Doses from Studies

Duration

Long-term / as needed before sun season

Administration

Subcutaneous implant (not injection)

When and how is Melanotan I taken?

Best Time to Take

Before the sunny season (approved implant); evening for unapproved injectables

Implant every 60 days (approved); community injectable use runs daily loading, then maintenance

Food Recommendation

With or without food

Why This Timing?

The approved implant is placed every 60 days ahead of expected sun exposure to build protective pigment. For unapproved injectable use, users report evening dosing to sleep through any nausea or flushing.

What are the side effects of Melanotan I?

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • ●Nausea (common)
  • ●Skin darkening (intended effect), including darkening of existing moles
  • ●Headache
  • ●Fatigue
  • ●Implant site reactions (approved Scenesse implant)

References

Research This Peptide Further

Frequently Asked Questions

What does Melanotan I do?

Melanotan I is the research name for afamelanotide (code CUV1647), a 13-amino-acid synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH), also written as [Nle4, D-Phe7]-alpha-MSH or NDP-MSH. Sold as Scenesse, it was approved by the EMA in 2014 and the FDA in 2019 to increase pain-free light exposure in adults with erythropoietic protoporphyria (EPP), one of a few approved melanocortin drugs alongside bremelanotide (Vyleesi) and setmelanotide (Imcivree). The approval covers only the 16 mg bioresorbable implant placed under the skin by a clinician. The injectable 'Melanotan I' sold online is not approved for anything.

How does Melanotan I work?

Afamelanotide binds and activates the melanocortin-1 receptor (MC1R) on pigment-producing melanocytes, driving production of eumelanin, the dark, photoprotective form of melanin. Two amino acid swaps from natural alpha-MSH - norleucine at position 4 and D-phenylalanine at position 7 - make it bind MC1R more tightly and resist breakdown, so it lasts far longer and acts more potently than the native hormone. The extra eumelanin absorbs and scatters light and also brings antioxidant and DNA-repair-supporting effects, which is why it raises the light dose EPP patients can tolerate before pain hits. Unlike Melanotan II, it is selective enough toward MC1R that it is not primarily a sexual-function or appetite agent.

Is Melanotan I FDA approved?

Yes, Melanotan I is FDA approved. FDA Approved (2019) as the Scenesse implant for Erythropoietic Protoporphyria only. Injectable 'Melanotan I' research products are not FDA approved. The label calls for a full-body skin exam twice a year because it darkens existing moles.

Is Melanotan I banned in sport?

Not on the WADA Prohibited List (2026); as afamelanotide it is an approved drug, so the S0 catch-all does not apply.

What are the side effects of Melanotan I?

Reported side effects include: Nausea (common), Skin darkening (intended effect), including darkening of existing moles, Headache, Fatigue, Implant site reactions (approved Scenesse implant). Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of Melanotan I?

Community-reported common dose: 500-1000 mcg daily (loading), then 500-1000 mcg 1-2x weekly (maintenance) (Daily during loading (1-2 weeks), then 1-2x weekly maintenance). Range: 250-1000 mcg per administration. Administration: Subcutaneous implant (not injection). Prescription drug. Dose set by prescriber per label. Not medical advice.

Related Peptides

Peptides commonly compared with Melanotan I or used in similar applications.

GHK-Cu

Clinical Trials

GHK-Cu is the copper(II) complex of GHK, a naturally occurring human tripeptide (glycyl-L-histidyl-L-lysine) found in blood plasma, saliva and urine, whose levels decline with age. It is researched and widely used in cosmetic skincare for skin regeneration, wound healing, collagen support and anti-aging. It is not an FDA-approved drug; it appears in over-the-counter cosmetics and as a research or compounded peptide, with most human evidence coming from small topical-skincare studies.

Skin & Hair

Snap-8

Research

SNAP-8 (Acetyl Octapeptide-3) is a synthetic eight-amino-acid topical cosmetic peptide, an extended cousin of Argireline that adds two residues to the same SNAP-25 mimic sequence. It is marketed as a needle-free way to soften expression lines, especially on the forehead and around the eyes. It is a cosmetic ingredient, not an approved drug, and the human evidence behind it is thin and mostly comes from the manufacturer.

Skin & Hair

Argireline

Research

Argireline is the trade name for acetyl hexapeptide-8 (sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2, also called acetyl hexapeptide-3), a synthetic peptide sold in anti-aging creams as a topical, needle-free alternative to Botox. It is designed to relax the muscle contractions behind expression lines. It is a cosmetic ingredient, not an FDA-approved drug, and the human efficacy data are genuinely mixed rather than settled.

Skin & Hair

Matrixyl

Research

Matrixyl is the trade name (Sederma) for palmitoyl pentapeptide-4, also written Pal-KTTKS, a collagen-fragment peptide attached to a fatty acid so it can cross skin. Unlike Botox-mimic peptides, it does not touch muscle: it signals skin cells to rebuild collagen, so it is aimed at fine lines, firmness and skin texture rather than expression wrinkles. It is a cosmetic ingredient with one of the better-documented topical studies in the peptide space, though far short of drug-grade proof.

Skin & Hair

Matrixyl 3000

Research

Matrixyl 3000 is Sederma's follow-up to the original Matrixyl, a fixed pair of two fatty-acid-tagged peptides: palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapeptide-7 (Pal-GQPR). The idea is a one-two punch: one peptide tells skin to rebuild collagen, the other calms the low-grade inflammation that wears collagen down. It is a cosmetic ingredient aimed at firmness, fine lines and aging skin, with supportive but mostly company-generated evidence.

Skin & Hair

Copper Peptide AHK-Cu

Research

AHK-Cu is a synthetic copper-bound tripeptide, alanine-histidine-lysine complexed with a copper ion, engineered mainly for hair and scalp products. It is the lesser-known sibling of the naturally occurring GHK-Cu copper peptide, designed in the lab specifically to push hair follicles to keep growing. It is a cosmetic and research ingredient, not an approved hair-loss drug, and its evidence is essentially limited to one notable lab study.

Skin & Hair

Want updates on Melanotan I research?

Get an email when we add new research here, when it is back in stock, or when the price drops.